VIDEO: Phase 3 dry AMD trial focuses on protecting photoreceptors
Click Here to Manage Email Alerts
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Reenie McCarthy of Stealth BioTherapeutics discusses a phase 3 clinical trial of elamipretide in dry age-related macular degeneration.
The trial targets a new FDA-approved endpoint of photoreceptor protection, building on promising results from phase 2 clinical trials, McCarthy said.
“By directly protecting the photoreceptors, which we saw was highly associated with improvements in low-light visual acuity with a significant number of patients gaining two or more lines, we think we are getting to the heart of what matters for patients living with this devastating progressive disease,” she said.
Collapse
Healio Interviews
Click Here to Manage Email Alerts